Castanon N, Bluthé R M, Dantzer R
INRA-INSERM U394, Neurobiologie Intégrative, Institut François Magendie, Bordeau, France.
Psychopharmacology (Berl). 2001 Feb;154(1):50-60. doi: 10.1007/s002130000595.
The hypothesis that proinflammatory cytokines play a causative role in the pathophysiology of depression has been recently tested by studying the effect of antidepressants on production of endogenous cytokines, and on sickness behavior induced by exogenous cytokines. In this last case, however, the effect of antidepressants has been only studied on the effect of peripherally administered cytokines.
The aim of the present study was to determine whether the antidepressant tianeptine can attenuate both peripheral and central cytokine actions.
Rats were injected IP with acute (10 mg/kg) or chronic (10 mg/kg, 2 times/day, 17 days) tianeptine. The effects of this treatment were assessed on the behavioral (social exploration, locomotion) and metabolic (food intake, body weight) alterations induced by peripheral or central administration of the cytokine inducer lipopolysaccharide (LPS) (250 microg/kg IP; 100 ng/rat ICV) or the prototypical proinflammatory cytokine interleukin-1 (IL-1)beta (15 microg/rat IP; 90 ng/rat ICV).
Chronic, but not acute, treatment with tianeptine attenuated the behavioral signs of sickness behavior induced by peripheral, but not central, LPS or IL-1beta.
This work, which is the first in vivo study assessing the effect of an antidepressant on centrally induced immune activation, shows a clear dissociation between peripheral and central cytokine effects, and suggests a peripheral site of action of tianeptine. It also provides the first evidence that the protective effects of classical antidepressants on LPS-induced sickness behavior extend to an atypical antidepressant, and that the protective effect of antidepressants also applies to IL-1beta.
促炎细胞因子在抑郁症病理生理学中起因果作用这一假说,最近通过研究抗抑郁药对内源性细胞因子产生的影响以及对外源性细胞因子诱导的疾病行为的影响进行了验证。然而,在后一种情况下,抗抑郁药的作用仅针对外周给予细胞因子的效果进行了研究。
本研究旨在确定抗抑郁药噻奈普汀是否能减弱外周和中枢细胞因子的作用。
给大鼠腹腔注射急性剂量(10毫克/千克)或慢性剂量(10毫克/千克,每日2次,共17天)的噻奈普汀。评估该治疗对由外周或中枢给予细胞因子诱导剂脂多糖(LPS)(250微克/千克腹腔注射;100纳克/大鼠脑室内注射)或典型促炎细胞因子白细胞介素-1(IL-1)β(15微克/大鼠腹腔注射;90纳克/大鼠脑室内注射)所诱导的行为(社交探索、运动)和代谢(食物摄入、体重)改变的影响。
噻奈普汀的慢性治疗而非急性治疗减弱了由外周而非中枢给予的LPS或IL-1β所诱导的疾病行为的行为体征。
这项首次评估抗抑郁药对中枢诱导的免疫激活作用的体内研究表明,外周和中枢细胞因子的作用存在明显分离,并提示了噻奈普汀的外周作用位点。它还首次证明了经典抗抑郁药对LPS诱导的疾病行为的保护作用扩展至一种非典型抗抑郁药,且抗抑郁药的保护作用也适用于IL-1β。